
    
      Randomized, double-blind, placebo-controlled, single ascending dose level study. On Day 1,
      eligibility of each subject will be confirmed, physical examination will be performed, and
      blood and urine for laboratories will be obtained. Each subject will be randomized, then will
      receive either a single IV, SC or IN dose of GLYX-13 or placebo.
    
  